To whom it may concern:
February 1, 2022
Whiz Partners Inc.

Signature on Japan Impact-Driven Financing Initiative
Whiz Partners Inc. (headquarters: Minato-ku, Tokyo; president & CEO, member of the board:
Atsushi Matsumura; hereinafter referred to as “the company”) has put its signature on the Japan
Impact-Driven Financing Initiative (secretariat: Japan Social Innovation and Investment Foundation)(Exhibit) that financial institutions declare actively addressing social and environmental issues withimpact-driven management.
Impact investment is aimed at generating positive and measurable social and environmental
impacts in addition to financial returns (performance). Traditional investing is measured on the twodimensions of risk and return. An investment that incorporates the third dimension, impact, into the
traditional ones, and that is intended to achieve both social and financial returns by grasping socialand environmental changes and the effects that occur as a result of business activities is called animpact investment.
The Japan Impact-Driven Financing Initiative will promote impact investment throughcooperation and collaboration between diverse and multiple financial institutions that believe that thepurpose of financial institutions is to actively address social and environmental issues by holisticallyunderstanding the impact. The initiative has been signed by twenty-seven financial institutions,
including the company.
For the Healthcare New Platform Fund*１ whose offering and investment were started in
September 2021, the company aims to expand the following social impacts through a high degree ofexpertise in the whole pharmaceutical industry and corporate management ability of the wholecompany group, agile and flexible business partnership ability regardless of nationality and businesscategory, and management policy and business promotion of investee companies.
(i) Enhancement of the access to healthcare
The World Bank and World Health Organization (WHO) reported that half of the world’s

population did not have access to basic health services in 2017. The company contributes to theenhancement of access to healthcare around the world through high-mix, low-volume drug
discovery and increasing the efficiency and industrialization of the drug discovery process and areduction in drug development costs.
(ii) Creation of new platform companies in the pharmaceutical sector facing industrial structure change
In the pharmaceutical sector, there is an industrial structure change in the drug development
process from the vertical integration model to the horizontal specialization model using
outsourcing. To respond to the horizontal specialization model, the company builds healthcare
platform companies with global competitiveness and then assists in the achievement of sustainable
and solid infrastructure development in the healthcare area and contributes to an increase inhealthy life spans.
(iii) Reduction in risk of infection under the pandemic
For contributing to the health of people, the company realizes the rapid supply of vaccines, whichbecame an issue during the recent infection pandemic, through the establishment of dual-use
messenger RNA API (active pharmaceutical ingredient) manufacturing plants that could
manufacture bio-pharmaceuticals in ordinary times and the switch to manufacturing of vaccines inan urgent time.
Comment from Atsushi Matsumura, President & CEO, Member of the Board
The Healthcare New Platform Fund, which is managed by the company, establishes companies byitself, raises money, and attracts the required talent and technology to actively promote businessdevelopment, become deeply involved in management, and actively address the social issues of theenhancement of access to healthcare, increase in healthy life spans, and reduction in the risk ofinfection. Therefore, we think that making and executing an impact-driven business plan enable us tosecure consistency as a company. We are obligated to provide financial returns (performance) toinvestors as a fund, and besides providing financial returns, we are responsible for ensuring thatinvestee companies continuously incorporate the mechanism for determining judgments according
to social goals, such as the SDGs, into corporate management. Based on the assumption that impact
investment is an optimum approach to fulfill the responsibility, we would like to largely contribute toactively addressing global environmental and social issues through impact-driven investment.

Healthcare New Platform Fund*１

The fund is an investment limited partnership that was established on September 28, 2021, forwhich the company serves as an unlimited liability partner. The fund makes investments mainlyin new healthcare platform companies, including Axcelead, Inc., the first healthcare platformcompany in Japan, and Arcalis, Inc., which set up a plant in Minamisoma-shi, Fukushima
Prefecture, and operates the sole CDMO business in Japan for APIs and drug products ofmessenger RNA pharmaceuticals and vaccine. For more details, please see the press release attime of establishment (http://www.whizp.com/wp-content/uploads/2021/10/1894_03.pdf).
（Exhibit）TOP | Japan Impact-driven Financing Initiative (impact-driven-finance-initiative.com)[Contact]Eri Yokota, public relations manager yokota@whizp.com